Terumo Corporation recently announced the successful completion of its acquisition of a Drug Product Plant and associated Quality Control Laboratory operations from WuXi Biologics in Leverkusen, Germany, with the transaction officially closing on September 30, 2025.

This strategic acquisition reinforces Terumo’s position in the Contract Development and Manufacturing Organization (CDMO) sector, expands its integrated service offerings, and enhances its ability to support biopharmaceutical companies in launching effective injectable treatment options. By integrating Terumo’s expertise, advanced technologies, and skilled team, the company aims to accelerate innovation and deliver greater value to pharmaceutical customers and their patients.

The newly acquired Leverkusen Drug Product Plant features state-of-the-art facilities compliant with current Good Manufacturing Practice (cGMP) standards and is staffed by highly skilled professionals with deep production know-how. Leveraging these assets, Terumo will offer fill & finish services for vials and polymer prefillable syringes, including device assembly. This move will enable the company to meet the growing demand for CDMO services, particularly in Europe and the United States, driven by the rapid expansion of the biopharmaceutical market.

Noritsugu Fujita, Division President, Pharmaceutical Solutions Division, Terumo, commented “Our expanded footprint in Europe and unique CDMO capabilities will empower biopharmaceutical companies to bring effective treatments for chronic diseases to market more efficiently.”

Currently, Terumo operates three CDMO production facilities at the Kofu, Fujinomiya, and Yamaguchi plants in Japan.  The company has consistently enhanced its production capacity in line with the expansion of the CDMO business.

In fact, Terumo has strengthened its capabilities by expanding production lines at the Yamaguchi factory. Additionally, new production lines are being installed in a newly constructed building at the Kofu factory, scheduled for completion by the end of 2025. With the establishment of this new CDMO base in Europe, Terumo is strengthening its global operations to better serve pharmaceutical companies both domestically and internationally.​

Terumo specializes in the development of pharmaceutical primary containers such as prefillable syringes and drug delivery devices, utilizing polymer materials optimized for pharmaceutical applications. The company also operates in the CDMO space for combination products that integrate pharmaceuticals and medical devices, leveraging its advanced manufacturing technologies. Global expansion of the CDMO business remains a key pillar of Terumo’s future growth strategy.

Marco Chiadò Piat, President, Pharmaceutical Solutions, Terumo added “With our integrated solution – from primary container and fill & finish capabilities to device assembly – customers can bring us their Active Pharmaceutical Ingredient (API) and leave with fully assembled auto-injectors. This is a win-win for both patients and healthcare system, as self-injection systems offer a more cost-effective and patient-friendly way to administer injectable drugs.”

Overview of the drug product plant acquired from WuXi Biologics
Location: Leverkusen, North Rhine-Westphalia, Germany
Site area of the plant: 13,000㎡
Description of business: CDMO for injectable products
Number of employees: Approximately 150

The Pharmaceutical Solutions Division of Terumo develops patient-oriented parenteral delivery solutions for therapeutic performance and safety. Globally trusted for quality and precision, Terumo offers pharmaceutical and medical device manufacturers around the world comprehensive product design and development services as well as a portfolio of injection, infusion, primary packaging, and CDMO solutions. www.terumopharmaceuticalsolutions.com

Terumo (TSE: 4543) is a global medical innovation company. Guided by an unwavering commitment to patients, and driven by the passion of our associates, we strive to fulfill our Group Mission of “Contributing to Society through Healthcare.” Founded in Tokyo in 1921, we provide a comprehensive range of solutions in the fields of therapeutic procedures, hospital operations, and life sciences in more than 160 countries and regions. www.terumo.com